313 related articles for article (PubMed ID: 38233727)
21. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
22. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
23. Protean role of epigenetic mechanisms and their impact in regulating the Tregs in TME.
Smiline Girija AS
Cancer Gene Ther; 2022 Jun; 29(6):661-664. PubMed ID: 34321625
[TBL] [Abstract][Full Text] [Related]
24. Treg programming and therapeutic reprogramming in cancer.
Moreno Ayala MA; Li Z; DuPage M
Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047
[TBL] [Abstract][Full Text] [Related]
25. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.
Liu Z; Li X; Gao Y; Liu J; Feng Y; Liu Y; Wang J; Wang C; Wang D; He J; Han W; Mei Q; Sun Y
Mol Cancer; 2023 May; 22(1):84. PubMed ID: 37189103
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances of RNA m
Ma S; Barr T; Yu J
Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
29. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
30. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review.
Wu X; Zhou Z; Cao Q; Chen Y; Gong J; Zhang Q; Qiang Y; Lu Y; Cao G
Front Immunol; 2023; 14():1268188. PubMed ID: 37753092
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
32. Reinvigorating exhausted CD8
Hossain MA; Liu G; Dai B; Si Y; Yang Q; Wazir J; Birnbaumer L; Yang Y
Med Res Rev; 2021 Jan; 41(1):156-201. PubMed ID: 32844499
[TBL] [Abstract][Full Text] [Related]
33. Small molecule inhibitors targeting regulatory T cells for cancer treatment.
García-Díaz N; Wei Q; Taskén K
Eur J Immunol; 2024 Feb; 54(2):e2350448. PubMed ID: 37937687
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy.
Hojjatipour T; Maali A; Azad M
Epigenomics; 2023 Feb; 15(4):249-266. PubMed ID: 37125432
[TBL] [Abstract][Full Text] [Related]
36. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
37. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
Singh D; Khan MA; Siddique HR
Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
[TBL] [Abstract][Full Text] [Related]
38. Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment.
McRitchie BR; Akkaya B
Front Immunol; 2022; 13():940052. PubMed ID: 36248808
[TBL] [Abstract][Full Text] [Related]
39. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modulation of immunotherapy and implications in head and neck cancer.
Zhou L; Xu N; Shibata H; Saloura V; Uppaluri R
Cancer Metastasis Rev; 2021 Mar; 40(1):141-152. PubMed ID: 33403469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
